Edwards Lifesciences Corporation (EW) has seen a range of strategic movements and performance indicators. A concerted focus on their heart-focused products and the corporation's robust Q4 and full-Year 2023 financial results underline the firm's strength within its core market. Investors should keep an eye on the company's adjusted EPS, which has banked mixed results, beating estimates in some cases. A notable strategic movement within the firm: the spin-off of their critical care unit in 2024. There's been an exciting increase in the overall stock holdings of EW with entities like SG Americas Securities LLC and Tobam raising their positions. However, others, like Wealthspire Advisors LLC and Janney Montgomery Scott LLC, have trimmed their hold on EW shares. Viewing from the retail investment space, if one had invested in Edwards Lifesciences 20 years ago, the investment would have yielded approximately $33,000 today. Notably, Edwards Lifesciences is largely controlled by institutional shareholders holding accounting for 84% of the ownership stakes of the business. Lastly, Edwards Lifesciences has had an executive reshuffle with the appointment of David Feinberg to the board and the retirement of chair, Michael Mussallem.
Edwards Lifesciences Corp EW News Analytics from Tue, 29 Aug 2023 07:00:00 GMT to Sun, 14 Jul 2024 18:49:56 GMT -
Rating 5
- Innovation 7
- Information 8
- Rumor -3
